Live Breaking News & Updates on ஆராய்ச்சி வணிக வளர்ச்சி

Stay updated with breaking news from ஆராய்ச்சி வணிக வளர்ச்சி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development


Published: May 05, 2021
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) Anavex Life Sciences Corp.  . (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dr. Adebayo (Bayo) Laniyonu, as Senior Vice President for Nonclinical Development. Dr. Laniyonu has over 24 years’ experience with the US Food and Drug Administration (FDA).
“Dr. Laniyonu has an accomplished track record of working within the FDA,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “His depth of experience makes him an excellent choice to provide objective perspective and manage the continuous nonclinical projects at Anavex.” ....

United Kingdom , Christopheru Missling , Adebayo Bayo Laniyonu , Andrewj Barwicki , Company Nasdaq , Award For Distinguished Service , Research Business Development , Advisory Committee , Nonclinical Development , Group Recognition Award , Anavex Life Sciences Corp , Department Of Health , Outstanding Service Award , Human Services , Drug Administration , University Of Glasgow , Michaelj Fox Foundation For Parkinson Research , Life Sciences , Senior Vice President , Chief Executive Officer , Drug Evaluation , Rare Diseases , Medical Genetics , Medical Imaging , Radiation Medicine , Medical Countermeasures ,